Ludovic Drouet

Ludovic Drouet

Auto-generated profile, based on publicly available information

Ludovic Drouet

CREATIF, Lariboisière Hospital, AP‐HP

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
SSStephane Manzo- Silberman
Stephane Manzo- Silberman
FCFrancis Couturaud
Francis Couturaud
ABAnne Bellemain‐Appaix
Anne Bellemain‐Appaix
EVEstelle Vautrin
Estelle Vautrin
AGAnne Gompel
Anne Gompel
FIfor the WAMIF Investigators
for the WAMIF Investigators
Background: The percentage of women <50 years of age hospitalized with myocardial infarction is increasing. We describe the clinical, morphological, and biological characteristics, as well as the clinical outcomes of this population. Methods and Results: This prospective, observational study included consecutive women <50 years of age admitted for myocardial infarction at 30 centers in France (May 2017–June 2019). The primary outcome was the composite of net adverse clinical events: all‐cause death, cardiovascular death, recurrent myocardial infarction, stent thrombosis, any stroke, or major bleeding occurring during hospitalization with a 12‐month follow up. Three hundred fourteen women were included. The mean age was 43.0 (±5.7) years, 60.8% presented with ST‐segment–elevation myocardial infarction, 75.5% were current smokers, 31.2% had a history of complicated pregnancy, and 55.1% reported recent emotional stress. Most (91.6%) women presented with typical chest pain. Of patients on an estrogen‐containing contraceptive, 86.0% had at least 1 contraindication. Of patients with ST‐segment–elevation myocardial infarction, 17.8% had myocardial infarction with nonobstructive coronary arteries and 14.6% had spontaneous coronary artery dissection, whereas 29.3% presented with multivessel vessel disease. During hospitalization, 11 net adverse clinical events occurred in 9 (2.8%) women, but no deaths or stent thromboses occurred. By 12 months, 14 net adverse clinical events occurred in 10 (3.2%) women; 2 (0.6%) died (from progressive cancer) and 25 (7.9%) had an ischemia‐driven repeat percutaneous coronary intervention. Conclusions: Most young women with myocardial infarction reported typical chest pain and had modifiable cardiovascular risk factors. History of adverse pregnancy outcomes and prescription of combined oral contraceptive despite a contraindication were prevalent, emphasizing the need for comprehensive cardiological and gynecological evaluation and follow‐up. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03073447.

1 August 2017 in EuroIntervention
Verified
Journal Article
Closed access
RGRobert van Geuns
Robert van Geuns
GSGeorgios Antonios Sideris
Georgios Antonios Sideris
NRNiels Van Royen
Niels Van Royen
RMRami El Mahmoud
Rami El Mahmoud
RDRoberto Diletti
Roberto Diletti
LDLudovic Drouet
Ludovic Drouet
The aim of the study was to investigate whether bivalirudin versus unfractionated heparin (UFH) reduces infarct size (IS) for primary percutaneous coronary intervention (PPCI) in large acute myocardial infarction (AMI). This multicentre open-label trial randomised 78 patients undergoing PPCI for large AMI to bivalirudin or UFH. The primary endpoint was IS, assessed by cardiac magnetic resonance (CMR) five days after PPCI. Secondary endpoints included index of microcirculatory resistance (IMR), CMR-assessed microvascular obstruction (MVO) and ejection fraction, and biomarkers for thrombin activity and cell injury. No difference was observed in mean IS at five days (25.0±19.7 g for bivalirudin vs. 27.1±20.7 g for UFH; p=0.75). Early MVO was numerically lower with bivalirudin (5.3±5.8 g vs. 7.7±6.3 g; p=0.17), with no significant difference in ejection fraction at 90 days (54.6±12.0% vs. 49.1±12.1%; p=0.11). In the biomarkers, thrombin-antithrombin complexes were reduced by 4.8 ug/L over the first day for bivalirudin versus an increase of 1.9 ug/L in the heparin arm (p=0.0003). Acute IMR was lower (43.5±21.6 vs. 68.7±35.8 mmHg×s, respectively; p=0.014). In a planned interim analysis, an approximate 11% reduction in IS was observed with bivalirudin; the trial was discontinued for futility. This study did not achieve its primary endpoint of significant infarct size reduction in PPCI by prolonged bivalirudin infusion compared to UFH, even though complete thrombin inhibition was achieved in the acute phase, with a lower myocardial microcirculation resistance at the end of the procedure.

1 October 2021 in Archives of Cardiovascular Diseases
Verified
Journal Article
Closed access
CSClaire Bal Dit Sollier
Claire Bal Dit Sollier
NBNatacha Berge
Natacha Berge
SHSara Hamadouche
Sara Hamadouche
CBCaren Brumpt
Caren Brumpt
ASAlain Stépanian
Alain Stépanian
JDJean-Guillaume Dillinger
Jean-Guillaume Dillinger

17 March 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
DDDiana Doukhi
Diana Doukhi
AAAgnes Aghetti
Agnes Aghetti
VSVirginie Siguret
Virginie Siguret
JLJulien Labreuche
Julien Labreuche
MDMaxime Delrue
Maxime Delrue
ICIsabelle Crassard
Isabelle Crassard
Background: Anemia has emerged as a risk factor for cerebral venous thrombosis (CVT) and has been associated with poorer outcomes. A specific association has been observed with microcytic anemia, most commonly caused by iron deficiency anemia (IDA). However, detailed data on the clinical, radiological, and therapeutic profile of CVT in patients with IDA remain limited. Methods: We analyzed consecutive patients with CVT and moderate or severe IDA from the prospective Lariboisière Hospital cohort with CVT (1998–2023). Patients with other types of anemia were excluded. Clinical, neuroimaging, treatment, and outcome data were compared with those of patients with CVT without anemia. Results: Among 616 patients with CVT, 64 (10.4%) had moderate or severe IDA. Most were women (96.9%), with chronic gynecological bleeding (eg, fibroids, adenomyosis) as the predominant cause. All received anticoagulation. Additional treatments included iron supplementation, blood transfusion, gynecological surgery, and gonadotropin‐releasing hormone analogs. Compared with patients without anemia (n=502), those with IDA more frequently presented with focal neurological deficits and parenchymal lesions (54.7% versus 35.3%, P =0.0025), particularly venous infarctions (32.8% versus 14.5%, P =0.0002). Despite more severe initial presentations, 1‐year functional outcomes did not significantly differ between groups (adjusted odds ratio for excellent outcome associated with IDA, 0.60 [95% CI, 0.23–1.52]). Conclusions: IDA is a prevalent comorbidity in CVT, affecting predominantly young women with benign, treatable causes of IDA. Although associated with more severe initial findings, long‐term outcomes did not differ from those of patients without IDA. Appropriate recognition and specific management of IDA should be considered in patients with CVT.

31 October 2021 in Annales de Cardiologie et d'Angéiologie
Verified
Journal Article
Closed access
MPMatthieu Perier
Matthieu Perier
GSGabriel Seret
Gabriel Seret
FHFlorent Huang
Florent Huang
JDJean- Guillaume Dillinger
Jean- Guillaume Dillinger
PHPr. Patrick Henry
Pr. Patrick Henry
HBHakim Benamer
Hakim Benamer

1 October 2004 in Journal de Gynécologie Obstétrique et Biologie de la Reproduction
Verified
Journal Article
Closed access
FLF. Larousserie
F. Larousserie
LDL. Drouet
L. Drouet
BRB. Rapp
B. Rapp
JLJ. Lansac
J. Lansac